NCT05518708View on ClinicalTrials.gov

A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

September 21, 2023

Study Completion Date

September 21, 2023

Conditions
Healthy
Interventions
DRUG

BI 3032950

BI 3032950

DRUG

Placebo

Placebo

Trial Locations (1)

2650

SGS Life Science Services - Clinical Research, Edegem

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05518708 - A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated | Biotech Hunter | Biotech Hunter